The abstract is read at the publisher; the summary is JClub's.
Continuous ocrelizumab over 10 years in relapsing multiple sclerosis is linked to a 24% lower hazard of 48-week confirmed disability progression versus delayed initiation.
- Why it matters: Disability progression in relapsing MS is a key treatment target, but long-term safety and comparative effectiveness beyond the initial trial period are critical to guide early therapy choices.
- What they did: OPERA I and II randomized patients with relapsing MS to ocrelizumab 600 mg every 24 weeks or interferon beta-1a for 2 years, then used an open-label extension to receive ocrelizumab for up to 8 additional years.
- The result: In 1656 randomized patients, 680 (82.2%) on continuous ocrelizumab remained free of 48-week CDP and 712 (86.1%) were free of PIRA, with relapse rates falling from 0.139 at year 1 to 0.016 at year 10 and adverse event rates not increasing during the 8-year extension.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.